Additionally, we acknowledge that tumor sizes differed by up to a factor of three between Luminal A and the more aggressive HER2+ and triple-negative BC subtypes, although cross-sectional areas remained largely comparable (3.8 ± 2.2 mm2, mean ± standard deviation), and therefore, a systematic bias from tumor size differences is unlikely. Here, ERBB2 is linked to breast cancer.